<DOC>
	<DOCNO>NCT00561925</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy 400 mg QD nevirapine extend release ( NVP XR ) formulation versus 200 mg BID nevirapine immediate release ( NVP IR ) ARV therapy naïve HIV-1 infect patient 48 week treatment . Secondary objective evaluate safety pharmacokinetics NVP XR NVP IR .</brief_summary>
	<brief_title>VERxVE Study Efficacy Safety Nevirapine XR Comparison Nevirapine IR With Truvada Naive HIV+ Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Inclusion criterion : 1 . Signed informed consent accordance Good Clinical Practice local regulatory requirement prior trial participation 2 . HIV1 infect male female &gt; = 18 year age positive serology ( ELISA ) confirm Western blot 3 . No previous antiretroviral treatment 4 . Males CD4+ count &gt; 50 &lt; 400 cells/ml female CD4+ count &gt; 50 &lt; 250 cells/ml 5 . Adequate renal function define calculated creatinine clearance ( CLCr ) great equal 50 mL/min accord CockcroftGault formula follow : Male : ( 140 age year ) x ( weight kg ) divide 72 x ( serum creatinine mg/dl ) = CLCr ( mL/min ) . Female : ( 140 age year ) x ( weight kg ) divide 72 x ( serum creatinine mg/dl ) x 0.85 = CLCr ( mL/min ) . 6 . Karnofsky score &gt; 70 ( see Appendix 10.4 ) 7 . An HIV1 viral load 1,000 copies/mL 8 . Willingness initiate CD4+ cell countguided chemoprophylaxis prevent important opportunistic infection define Appendix 10.2 9 . Willingness abstain ingest substance may alter plasma study drug level interaction cytochrome P450 system ( list Appendix 10.3 ) study . 10 . For center participate PK substudy : Written inform consent accordance GCP local legislation participation PK substudy . Refusal participate PK substudy exclusion criterion participation trial . Only study center previous experience equip handle PK sample eligible participation substudy . Exclusion criterion : 1 . Active drug abuse chronic alcoholism investigator 's discretion 2 . Active hepatitis B C disease , define HBsAgpositive HBVDNApositive HCVRNApositive 3 . Female patient childbearing potential : pregnant screening ; breast feeding ; plan become pregnant ; willing use barrier method contraception , ; willing use method contraception ethinyl estradiol contain oral contraceptive Note : During participation study , female male use barrier method contraception addition instead ethinyl estradiol contain oral contraceptive . 4 . Laboratory parameter &gt; DAIDS Grade 2 5 . ALT/AST &gt; DAIDS Grade 1 6 . Hypersensitivity ingredient test product 7 . Previous use Viramune® ( nevirapine ) antiretroviral agent ( include use single dose NVP prevention mother child transmission ) 8 . Resistance NNRTIs either one component Truvada® ( emtricitabine tenofovir disoproxil fumarate ) lamivudine ( 3TC ) base HIV1 genotypic resistance test report obtain screen 9 . Patients receive concomitant treatment permit , describe prescribe information 10 . Use investigational medication ( experimental agent study regimen ) within 30 day study entry trial 11 . Use immunomodulatory drug within 30 day study entry trial ( e.g. , interferon , cyclosporin , hydroxyurea , interleukin 2 ) 12 . Patients diagnose malignant disease 13 . Patients opinion investigator candidate inclusion study 14 . Patient Progressive Multifocal Leukoencephalopathy ( PML ) , Visceral Kaposi 's Sarcoma ( KS ) , and/or lymphoma 15 . Any AIDS defining illness unresolved , symptomatic stable treatment least 12 week screen visit</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>